GLP1R and obesity disorder: Treatments for obesity, such as glucagon-like peptide 1 (GLP-1) analogues (liraglutide and semaglutide), can be used.67 Early identification of those metabolic changes and their proper treatment are crucial to reduce CVR in women with POS.